Yuyu Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 16, 2022 at 03:47 am EDT
Share
Yuyu Pharma, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported negative sales was KRW 0.00013 million compared to sales of KRW 0.00045 million a year ago. Net loss was KRW 1,399.58 million compared to KRW 157.6 million a year ago. Basic loss per share from continuing operations was KRW 88 compared to KRW 14 a year ago. Diluted loss per share from continuing operations was KRW 88 compared to KRW 14 a year ago. Basic loss per share was KRW 88 compared to KRW 14 a year ago.
For the six months, negative sales was KRW 0.00015 million compared to sales of KRW 0.00041 million a year ago. Net loss was KRW 1,692.73 million compared to net income of KRW 119.7 million a year ago. Basic loss per share from continuing operations was KRW 110 compared to KRW 1 a year ago. Diluted loss per share from continuing operations was KRW 110 compared to KRW 1 a year ago. Basic loss per share was KRW 110 compared to KRW 1 a year ago.
Yuyu Pharma, Inc. is a Korea-based company engaged in the provision of pharmaceutical products. The Company produces prescription drugs such as circulatory improvement agents, antiplatelet agents, osteoporosis drugs, antiulcerants, bone metabolism ameliorants, gout preparative drugs, antidepressants, anti-diabetic agents, antitubercular agents, antihypertensive agents, angina pectoris drugs, antibiotics, hemorrhoidal and varicose preparations, topical corticosteroids and others, as well as non-prescription drugs such as vitamins and digestive agents. It also provides healthcare supplements and quasi drugs. In addition, the Company is involved in the provision of medicines for geriatric diseases such as osteoporosis, dementia, stroke and others.
YUYU PHARMA, INC. 